Why the study?
The rising global prevalence of obesity, insulin resistance, and related metabolic complications prompted the exploration of brown adipose tissue to combat obesity and treat metabolic disorders.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Brown adipose tissue is highlighted as a potential therapeutic target for managing obesity, insulin resistance, and dyslipidemia through increased energy expenditure.
The increased worldwide prevalence of obesity, insulin resistance, and their related metabolic complications have prompted the scientific world to search for new possibilities to combat obesity. Brown adipose tissue (BAT), due to its unique protein uncoupling protein 1 (UPC1) in the inner membrane of the mitochondria, has been acknowledged as a promising approach to increase energy expenditure. Activated brown adipocytes dissipate energy, resulting in heat production. In other words, BAT burns fat and increases the metabolic rate, promoting a negative energy balance. Moreover, BAT alleviates metabolic complications like dyslipidemia, impaired insulin secretion, and insulin resistance in type 2 diabetes. The aim of this review is to explore the role of BAT in total energy expenditure, as well as lipid and glucose homeostasis, and to discuss new possible activators of brown adipose tissue in humans to treat obesity and metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Maliszewska et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: